BSE Live
Mar 16, 16:01Prev. Close
370.10
Open Price
369.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 16, 15:59Prev. Close
368.75
Open Price
370.00
Bid Price (Qty.)
366.15 (100)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of SMS Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 8.07 | 5.84 | 0.48 | 8.04 | 7.20 | |
| Diluted EPS (Rs.) | 8.07 | 5.84 | 0.48 | 8.04 | 7.20 | |
| Cash EPS (Rs.) | 11.59 | 9.56 | 4.28 | 11.84 | 9.83 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 75.92 | 67.39 | 58.49 | 58.33 | 50.59 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 75.92 | 67.39 | 58.49 | 58.33 | 50.59 | |
| Dividend / Share(Rs.) | 0.40 | 0.40 | 0.30 | 0.30 | 0.30 | |
| Revenue from Operations/Share (Rs.) | 88.29 | 83.79 | 61.67 | 61.41 | 66.53 | |
| PBDIT/Share (Rs.) | 16.49 | 14.33 | 7.04 | 14.14 | 14.71 | |
| PBIT/Share (Rs.) | 12.62 | 10.61 | 3.24 | 10.34 | 12.08 | |
| PBT/Share (Rs.) | 10.53 | 7.84 | 0.66 | 8.11 | 10.76 | |
| Net Profit/Share (Rs.) | 7.71 | 5.84 | 0.48 | 8.04 | 7.20 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 18.67 | 17.10 | 11.41 | 23.02 | 22.11 | |
| PBIT Margin (%) | 14.29 | 12.65 | 5.26 | 16.83 | 18.16 | |
| PBT Margin (%) | 11.92 | 9.35 | 1.06 | 13.20 | 16.17 | |
| Net Profit Margin (%) | 8.73 | 6.96 | 0.78 | 13.08 | 10.82 | |
| Return on Networth / Equity (%) | 10.15 | 8.66 | 0.82 | 13.77 | 14.23 | |
| Return on Capital Employed (%) | 12.98 | 12.19 | 4.16 | 12.75 | 16.08 | |
| Return on Assets (%) | 5.76 | 4.62 | 0.44 | 7.70 | 7.34 | |
| Total Debt/Equity (X) | 0.46 | 0.49 | 0.51 | 0.53 | 0.51 | |
| Asset Turnover Ratio (%) | 0.69 | 0.72 | 0.58 | 0.61 | 0.77 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.72 | 1.62 | 1.61 | 1.92 | 1.59 | |
| Quick Ratio (X) | 0.84 | 0.91 | 0.73 | 0.64 | 0.88 | |
| Inventory Turnover Ratio (X) | 3.02 | 1.86 | 1.26 | 1.99 | 2.35 | |
| Dividend Payout Ratio (NP) (%) | 4.95 | 5.13 | 62.17 | 3.73 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 3.29 | 3.13 | 7.01 | 2.53 | 0.00 | |
| Earnings Retention Ratio (%) | 95.05 | 94.87 | 37.83 | 96.27 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 96.71 | 96.87 | 92.99 | 97.47 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 2,151.86 | 1,748.52 | 734.33 | 1,007.49 | 1,231.25 | |
| EV/Net Operating Revenue (X) | 2.75 | 2.47 | 1.41 | 1.94 | 2.19 | |
| EV/EBITDA (X) | 14.72 | 14.41 | 12.32 | 8.42 | 9.88 | |
| MarketCap/Net Operating Revenue (X) | 2.41 | 2.13 | 0.94 | 1.53 | 1.87 | |
| Retention Ratios (%) | 95.04 | 94.86 | 37.82 | 96.26 | 0.00 | |
| Price/BV (X) | 2.80 | 2.64 | 0.99 | 1.61 | 2.46 | |
| Price/Net Operating Revenue | 2.41 | 2.13 | 0.94 | 1.53 | 1.87 | |
| Earnings Yield | 0.04 | 0.03 | 0.01 | 0.09 | 0.06 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
16.03.2026
15.03.2026
13.03.2026
13.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth